Bubs Australia has entered into a manufacturing and licensing agreement for goat’s milk infant formula in China with Heilongjiang Ubeite Dairy Group.
Sydney-listed Bubs Australia said the “ultra-premium” formula will be made in accordance with new standards in China coming into force in February. The product has been developed specifically for the local market using the A2 goat-milk protein, the company added.
Go deeper with GlobalData
While Bubs Australia already sells milk powder in the country under its English brand names, the deal marks a first for the company in onshore manufacturing. A joint venture will be set up for the purpose, with the Australian business holding a majority.
In the deal struck with “related parties” of Heilongjiang Ubeite Dairy Group (HUG), the New South Wales-based business said the Chinese entities will apply for a State Administration for Market Regulation (SAMR) licence.
The Chinese parties are already SAMR-compliant but will require new authorisation under the upcoming so-called GB regulations – an acronym of the anglicised Guojiabiaozhun.
Announced in March 2021, the new rules apply to infant formula not sold via cross-border e-commerce channels.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe formula will be marketed in China exclusively for Bubs Australia, which said the new registration will give the company access to the remaining 80% of the AUD40bn (US$25.6bn) local market.
Bubs Australia expects to begin sales in the second half of its fiscal year that started on 1 July, subject to receiving SAMR registration.
Founder and CEO Kristy Carr said: “We are pleased to announce this important milestone for the company to renew an existing registered SAMR brand slot for Bubs China label Goat Milk infant-formula products in partnership with a reputable Chinese infant-formula manufacturer.”
She added that in fiscal 2022, Bubs’ revenue from its English formula varieties grew 179% to more than AUD42m.
HUG has also “granted first right of refusal” for Bubs Australia to secure SAMR approval for its ultra-premium A2 cow’s milk formula under its Supreme A2 brand.
The JV entails a partnership with Zhitong (Hangzhou) Health Technology Co., with Bubs holding 75%. The venture will enter a manufacturing agreement with a related part of HUG, Zhikang (Hangzhou) Health Technology Co.
Strong growth in China – revenue was up 166% year-on-year, representing 55% of Bubs Australia’s sales – helped to underpin record sales for the company in its last financial year. In the 12 months to 30 June, group revenue more than doubled to AUD89.3m (US$57.5m).
